2QG.F QUANTUM GENOMICS EO -40
- Market cap
- EUR 4.26M
- P/E
- -
- P/B
- 0.00x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2024.
Is 2QG.F undervalued?
Graham numberThe Graham number of QUANTUM GENOMICS EO -40 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
QUANTUM GENOMICS EO -40 fundamental analysis
No fundamental analysis for QUANTUM GENOMICS EO -40 yet.
QUANTUM GENOMICS EO -40 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About QUANTUM GENOMICS EO -40
Quantum Genomics Société Anonyme is in the process of liquidation of its remaining assets. Previously, the company was engaged in the development of drugs to treat cardiovascular diseases. Quantum Genomics Société Anonyme was incorporated in 2005 and is headquartered in Paris, France.
Full company profileQUANTUM GENOMICS EO -40 financial statements
QUANTUM GENOMICS EO -40 annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | 116K | 605K | 10.1K | 0.00 |
| Gross Profit | -18.3M | -28.9M | -1.43M | -1.15M |
| Operating Income | -19.2M | -30.1M | -2.76M | -1.47M |
| EBITDA | -18.9M | -30.2M | -3.13M | -8.84M |
| Net Income | -16.6M | -24.9M | -3.17M | -8.89M |
| EPS | -0.61 | -0.72 | -0.09 | -0.13 |
| Balance Sheet | ||||
| Total Assets | 22.6M | 23.7M | 3.75M | 355K |
| Total Liabilities | 11.2M | 20.1M | 3.31M | 2.81M |
| Shareholders' Equity | 11.4M | 3.61M | 437K | -2.46M |
| Cash & Short-term Investments | 8.54M | 10.4M | 3.55M | 301K |
| Cash Flow | ||||
| Operating Cash Flow | - | -20.2M | - | - |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | - | -20.2M | - | - |
| Ratios | ||||
| ROE | -144.9% | -691.2% | -726.2% | - |
| ROA | -73.3% | -105.4% | -84.6% | -2,507.4% |
| Net Profit Margin | -14,246.3% | -4,121.7% | -31,520.3% | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
QUANTUM GENOMICS EO -40 dividends
QUANTUM GENOMICS EO -40 has not paid dividends in the last 5 fiscal years.
Who owns QUANTUM GENOMICS EO -40
- Insiders 36.09%
- Institutions 5.80%
- Public & others 58.11%
- Shares outstanding 69.7M
- Free float 59.7M
QUANTUM GENOMICS EO -40 company profile
- Company name
- QUANTUM GENOMICS EO -40
- Ticker
- 2QG.F
- ISIN
- FR0011648971
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1
- Fiscal year end
- December
- Address
- 6, rue Cambacérès, Paris, France, 75008
- Phone
- 33 1 85 34 77 70
- Website
- quantum-genomics.com
About QUANTUM GENOMICS EO -40
Quantum Genomics Société Anonyme is in the process of liquidation of its remaining assets. Previously, the company was engaged in the development of drugs to treat cardiovascular diseases. Quantum Genomics Société Anonyme was incorporated in 2005 and is headquartered in Paris, France.
QUANTUM GENOMICS EO -40 management
1- Mr. Mathieu BigoisCEO & Chairman of the Board